ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT01268150
Brief Title: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

First Submitted : December 28, 2010
First Submitted that Met QC Criteria : December 28, 2010
First Posted : December 29, 2010 (Estimate)

Results First Submitted : May 11, 2016
Results First Submitted that Met QC Criteria : June 28, 2016
Results First Posted : August 9, 2016 (Estimate)

Last Update Submitted that Met QC Criteria : June 28, 2016
Last Update Posted : August 9, 2016 (Estimate)